title: Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?
abstract: A small peptide, OP3-4, blocks receptor activator of NF-κB from binding to its ligand, receptor activator of NF-κB ligand (RANKL), and was reported recently to inhibit bone resorption, promote bone formation and protect cartilage in a preclinical rheumatoid arthritis model. The latter effects may result from inhibition of RANKL reverse signalling in osteoblasts and chondrocytes. Whether other RANKL inhibitors, such as denosumab, share this action is not known, but OP3-4 at least has potential to provide anabolic treatment for both systemic and focal bone loss in inflammatory arthritis.
authors.affiliation: St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, VIC, 3065, Australia. nsims@svi.edu.au.|Department of Medicine at St. Vincent's Hospital Melbourne, The University of Melbourne, 41 Victoria Pde, Fitzroy, VIC, 3065, Australia. nsims@svi.edu.au.
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Sims
authors.affiliation: Department of Medicine at St. Vincent's Hospital Melbourne, The University of Melbourne, 41 Victoria Pde, Fitzroy, VIC, 3065, Australia. evange.romas@svha.org.au.|Department of Rheumatology, St. Vincent's Hospital Melbourne, 41 Victoria Pde, Fitzroy, VIC, 3065, Australia. evange.romas@svha.org.au.
authors.forename: Evange
authors.initials: E
authors.lastname: Romas
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D001862:Bone Resorption / Q000188:drug therapy*; D000069448:Denosumab / Q000494:pharmacology; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology*; D010012:Osteogenesis / Q000187:drug effects*; D053245:RANK Ligand / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; C484520:OP3-4 peptide; D009842:Oligopeptides; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab